LGA
ABBV icon

Lebenthal Global Advisors’s AbbVie ABBV Stock Holding History

Lebenthal Global Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-200
Closed -$45.7K – 193
2025
Q4 		$45.7K Buy
+200
New +$45.6K 0.01% 182

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Lebenthal Global Advisors's ABBV Position: Q1 2026 in Review

Lebenthal Global Advisors increased its AbbVie (ABBV) stake by 41% in Q1 2026, buying an estimated $243K and bringing the position to 3,744 shares worth $814K. The position accounts for 0.12% of the portfolio, ranked #128.

Lebenthal Global Advisors first reported a position in ABBV in Q4 2020 and has held it in 22 quarters since. The position peaked at $1.25M in Q1 2022. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Lebenthal Global Advisors held 3,744 shares of AbbVie worth $814K as of Q1 2026.
  • Lebenthal Global Advisors bought 1,096 AbbVie shares in Q1 2026, an estimated $243K.
  • AbbVie made up 0.12% of Lebenthal Global Advisors's portfolio in Q1 2026, its #128 holding.
  • Lebenthal Global Advisors first reported a position in AbbVie in Q4 2020 and has held it in 22 quarters since.
  • Lebenthal Global Advisors's AbbVie position peaked at $1.25M in Q1 2022.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Lebenthal Global Advisors's 13F filing for Q1 2026, filed 14 May 2026.